News | July 20, 2012

Optical Coherence Tomography (OCT) Aids Carotid Stenting, Says Study

July 20, 2012 — The ability to see inside the arteries of vascular disease patients in high resolution before and during stenting procedures can offer valuable information. A new study of optical coherence tomography (OCT) in the Journal of Endovascular Therapy confirms the safety and feasibility of this imaging technique in the carotid arteries. A number of physicians lend their support to OCT as a means of gaining more knowledge of cardiac disease and improving the stenting procedure. However, because of cost issues, OCT still has a long road to travel to become widely utilized.

OCT is an invasive intravascular imaging system that produces high-resolution images using light rather than ultrasound. Its resolution is 10 times higher than that of any other clinically available diagnostic imaging method, and it can provide images of tissues at nearly histological resolution. Limitations of OCT include interference by blood flow and the degree of tissue penetration it can achieve.

In the current study, 25 patients undergoing carotid artery stenting also underwent OCT before stent deployment, immediately after stent placement and following post-dilation of the stent. The OCT technique had a success rate of 97.3 percent, and no complications occurred for the patients during the procedure or while in the hospital.

Through the use of OCT in the study, physicians were able to see rupture of the fibrous cap, plaque prolapse and stent malapposition in patients. As authors of the commentaries note, future applications could reveal further details that increase understanding of carotid stenting and influence clinical policies regarding its use.

Carotid artery stenting has not reached its predicted potential, in part owing to a lack of reimbursement in the United States and mixed results from European trials. OCT may provide evaluation of critical aspects of carotid artery stenting. Additionally, more evidence from OCT clinical research could help health authorities realize the value of the carotid artery stenting procedure.

For more information: www.jevt.org

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init